Success in the Pharmaceutical Business: What Changed From the 1980s to 2026

GXgate Editorial


N. F.
CHC International Business Associate
TABOR, Slovenia

C. S.
Pharmaceuticals
Gujarat, India

R. W.
Sales manager
Wuhan, China

R. R.
Business Development
Buenos Aires, Argentina

M. N.
Sales Representative
Butler, United States

D. P.
Pricing Lead
Curitiba, Brazil

R. Y.
Senior Business Development Manager
Amman, Jordan

H. O.
marketing manager
Hargeisa, Somalia

G. B.
Director
naples, Italy

M. H.
Snr Business Development Manager
London, United Kingdom

X. L.
manager
xian, China

R. S.
Senior Business Development Manager
Amman, Jordan

A. M.
CEO
Bogota, United States

U. A.
Manager
Abidjan, Ivory Coast

Y. C.
Int’l Business Dept.
Taizhou, China

M. G.
Director Business Development
Majadahonda, Spain

I. J.
Director
Nakhchivan, Azerbaijan

Z. C.
manager
xiamen, China

G. M.
DGM
AURANGABAD, India

H. J.
sales
Hangzhou, China
Short answer

In the 1980s a pharmaceutical company could prosper on a few patented products, a strong sales force and a protected home market; regulators judged a product mainly at the point of approval. Since then generic competition, global supply chains and continuous regulatory scrutiny have turned the industry into one where advantage is earned again every year. The companies that endure in 2026 share five habits: they choose molecules and markets before competitors crowd them, treat quality and data integrity as a commercial asset, know and control where every critical ingredient comes from, can file in several regions from one dossier, and keep enough financial room to absorb a price collapse, a warning letter or a tariff. Companies fail when they rely on a single one of these and neglect the rest.

The pharmaceutical industry rarely has a quiet year. Prices for older generics fall until some products are no longer worth making. Inspections reach further into laboratory records than ever before. In 2026 the United States introduced tariffs on patented medicines, and both Washington and Brussels are rewriting the rules on where medicines should be made. Yet in the same conditions some companies grow, some stand still and some disappear.

This article looks at the industry over four decades—what made a company flourish in the 1980s, what changed in trade and regulation, and which factors decide survival now. It is written for the companies that use GXgate to find partners: manufacturers, licensors, distributors and buyers who need to judge not only a product, but the company behind it. The data comes from public sources listed under each chart.

Five factors that separate durable companies from fragile ones

None of these is new. What changed is that each one is now tested continuously, not once.

Does the company choose molecules, dosage forms and markets before they become crowded?
Portfolio
Would its inspection history and data integrity survive a buyer’s or regulator’s close review?
Quality
Does it know, and control, where its critical starting materials and APIs come from?
Supply
Can one dossier and one site support registrations in several regions?
Reach
Can its balance sheet absorb a price collapse, a failed batch or a new tariff without a forced sale?
Resilience

The 1980s: Patents, Sales Forces and Protected Markets

A successful research-based company in the early 1980s looked much the same in New York, Basel, London or Tokyo. It discovered small-molecule drugs largely in its own laboratories, made the active ingredient and the finished product in its own plants, and sold through a large field force that visited doctors directly. The decade produced the first true “blockbusters”: products such as anti-ulcer drugs that earned more than a billion dollars a year. A handful of such products could carry a company for a decade.

Three conditions made that model work.

  • Long, lightly contested exclusivity. When a patent expired, competition arrived slowly. Before 1984, a US generic manufacturer usually needed its own safety and efficacy data to win approval, which few could afford. Only about one prescription in five was filled with a generic.
  • National markets. Each country had its own regulator, its own dossier format and often its own price controls. A company that was strong at home was protected by the cost a foreign competitor faced to register there.
  • Approval as the main hurdle. Good manufacturing practice existed, but inspection focused on the plant and the paperwork, not on audit trails in laboratory software. Once a product was approved, the regulatory relationship was comparatively quiet.

1984: the law that created the modern generic industry

The US Drug Price Competition and Patent Term Restoration Act of 1984, known as Hatch-Waxman, changed the economics on both sides. Generic manufacturers could file an abbreviated application relying on the originator’s clinical findings and showing bioequivalence, and could challenge patents before they expired. Originators received patent-term restoration for time lost in regulatory review. The trade was explicit: stronger protection during exclusivity, much faster competition after it.

At the same time, other countries were building generic capability by different routes. India’s Patents Act of 1970 recognised process patents but not product patents for medicines, which allowed Indian companies to develop new routes to molecules still patented elsewhere. Several of today’s large Indian manufacturers were founded or grew rapidly in this period, building the process-chemistry skills that later made the country a leading API supplier. In Europe, Italian and Spanish fine-chemical producers supplied APIs to generic companies across the continent.

Four Decades of Change in Trade and Regulation

The changes did not arrive at once. Each decade added a layer, and companies that adapted to one layer were sometimes caught by the next.

  1. 1984Hatch-Waxman creates the US abbreviated generic pathway and patent-term restoration.
  2. 1990ICH is founded to harmonise technical requirements between Europe, Japan and the United States.
  3. 1995The WTO TRIPS agreement takes effect, committing members to product patents for medicines; India complies from 2005.
  4. 1996–2004Mergers create Novartis, AstraZeneca, GSK and Sanofi-Aventis, and Pfizer absorbs Warner-Lambert and Pharmacia.
  5. 2001–2003China joins the WTO; the Common Technical Document becomes the standard dossier format in the EU.
  6. 2010–2012The US biosimilar pathway is created; major patent expiries, including atorvastatin in 2011; GDUFA brings generic user fees and foreign-inspection parity.
  7. 2018–2019Nitrosamine impurities trigger worldwide sartan recalls; EU serialisation under the Falsified Medicines Directive applies.
  8. 2020–2022The pandemic exposes supply concentration; the US Inflation Reduction Act introduces Medicare price negotiation.
  9. 2025BIOSECURE provisions enacted in the US defence authorisation act; EU institutions reach political agreement on the pharmaceutical package.
  10. 2026First negotiated Medicare prices apply; US Section 232 tariffs on patented medicines take effect; provisional agreement on the EU Critical Medicines Act.

Harmonisation lowered the cost of reaching new markets

ICH guidelines and the Common Technical Document gave companies a common technical language. A file written for one major region could be adapted for others rather than rebuilt. This favoured companies that invested in regulatory capability early: a single well-built dossier could support registrations in dozens of countries, often through licensing partners. GXgate’s guide to evaluating a generic dossier before in-licensing shows how much of a dossier’s value now depends on whether it travels.

Trade opened supply chains—then concentrated them

Through the 1990s and 2000s, API and intermediate production moved towards India and China, where process chemistry was strong and costs were lower. For generic companies, buying APIs on the open market replaced owning the whole chain. The result was cheaper medicines and, over time, heavy dependence on a small number of sources for some molecules and key starting materials.

Regulation moved from a gate to a continuous test

The largest change for manufacturers is that compliance no longer ends at approval. Electronic-records rules, data-integrity enforcement, foreign inspections funded by user fees, impurity limits applied retrospectively to marketed products, serialisation and stricter sterile-manufacturing rules all apply to products already on the market. A warning letter or import alert can now remove a product—or a whole site—from a market for years.

How the Market Shifted from Value to Volume

Hatch-Waxman worked as intended. Generic medicines went from about a fifth of US prescriptions to about nine in ten. Most of the value in the market, however, stayed with patented products.

Generic share of US prescriptions, selected years

Percent of prescriptions dispensed that were generic

Line chart. Generic share of US prescriptions was 19 percent in 1984, 75 percent in 2009, 90 percent in 2019 and 89 percent in 2025. 0%25%50%75%100% 19841995200520152025 1984: about 19% of prescriptions were generic 2009: 74.5% 2019: about 90% 2025: 89% 19%75%90%89% Hatch-Waxman Act

Sources: 1984 and 2009 from published analyses of Hatch-Waxman; 2019 and 2025 from the Association for Accessible Medicines’ savings reports. The line connects published points; intermediate years are not shown, and sources differ slightly in method.

Show data
YearGeneric share of prescriptions
1984~19%
200974.5%
2019~90%
202589%
89%of US prescriptions filled in 2025 were generics
11.6%of US prescription-drug spending went on those generics
$106bnspent on generics, against $804bn on branded medicines

Those three figures, from AAM’s 2026 report on 2025 data, describe two different industries sharing one market. Branded companies earn most of the revenue from a minority of prescriptions. Generic companies supply almost all the volume and compete on cost and reliability.

Why being the fifth entrant rarely works

The price of a generic depends heavily on how many companies make it. FDA’s analysis of products that first faced generic competition between 2015 and 2017 shows how quickly the margin disappears.

Generic price as a share of the brand price before generic entry

By number of generic manufacturers, based on average manufacturer price (AMP)

Bar chart. With one generic manufacturer the generic price is 61 percent of the pre-entry brand price; with two, 46 percent; with four, 21 percent; with six or more, below 5 percent. 0%25%50%75%100% 1 generic manufacturer: 61% of brand price (39% lower) 2 generic manufacturers: 46% of brand price (54% lower) 4 generic manufacturers: 21% of brand price (79% lower) 6 or more generic manufacturers: below 5% of brand price (more than 95% lower) 61%46%21%<5% 1 generic2 generics4 generics6 or more

Source: FDA, Generic Competition and Drug Prices (Conrad and Lutter, December 2019), retail pharmacy sales, products with first generic entry 2015–2017. Using pharmacy invoice prices the declines are smaller for one to four competitors (31%, 44% and 73%).

Show data
Generic manufacturersPrice reduction vs brandPrice as % of brand
139%61%
254%46%
479%21%
6 or more>95%<5%

This curve explains more corporate failures than any regulation. A company that enters an oral solid molecule as the sixth or eighth supplier competes for a few percent of the original price, against rivals with older, fully depreciated plants. Buyers have also consolidated: in the United States a small number of purchasing groups negotiate on behalf of most pharmacy demand, which strengthens their hand against any single supplier.

Companies that prosper in generics therefore tend to do one or more of the following: file early for difficult products—complex injectables, inhalers, modified-release forms, peptides, biosimilars—where fewer competitors can follow; integrate backwards into the API so they control the largest cost; or build a portfolio across many countries so that no single market’s price collapse is decisive. The same logic underlies GXgate’s apixaban patent-expiry analysis: the commercial question is always how many others will arrive, and when.

Innovation Became Far More Expensive

For research-based companies the opposite pressure applies. The cost of bringing a new drug to approval—including the cost of failures and of the capital tied up during development—has risen steeply in each generation of studies.

Estimated cost to develop one approved new drug

Capitalised cost including failures, constant 2013 US dollars, by period in which drugs entered clinical testing

Bar chart. Estimated cost per approved new drug was 179 million dollars for drugs from the 1970s, 413 million for the 1980s, 1.04 billion for the 1990s and 2.56 billion for the 2000s to early 2010s, all in 2013 dollars. $0$1.0bn$2.0bn$3.0bn 1970s: about $179 million 1980s: about $413 million 1990s: about $1,044 million 2000s to early 2010s: about $2,558 million $179m$413m$1.04bn$2.56bn 1970s1980s1990s2000s–early 2010s Hansen, 1979DiMasi et al., 1991DiMasi et al., 2003DiMasi et al., 2016

Source: Tufts Center for the Study of Drug Development, as summarised with the 2014 cost study (DiMasi, Grabowski and Hansen, Journal of Health Economics, 2016). Estimates cover new chemical and biological entities from a sample of large companies and are disputed by some researchers; they show the direction of change, not the cost of any single programme.

Show data
PeriodStudyCost per approved drug (2013 $)
1970sHansen, 1979$179m
1980sDiMasi et al., 1991$413m
1990sDiMasi et al., 2003$1,044m
2000s–early 2010sDiMasi et al., 2016$2,558m

The 1980s model—discover in-house, develop in-house, sell in-house—could not absorb that increase. Large companies responded first by merging, which bought pipelines and cut overlapping costs, and then by buying or licensing molecules from smaller biotechnology companies. Today much of the late-stage pipeline of large companies originates elsewhere, and a growing share of in-licensed molecules comes from Chinese biotech companies as well as from the US and Europe. Manufacturing followed the same path: much of it is now done by contract manufacturers and CDMOs. The differences between those partners are explained in GXgate’s comparison of API manufacturers, CMOs and CDMOs.

Price regulation adds a further squeeze. US Medicare price negotiation, with the first negotiated prices applying from January 2026, shortens the period in which a small-molecule drug earns its full return. In Europe, the reformed pharmaceutical legislation agreed in December 2025 adjusts regulatory protection periods and ties part of the protection to conditions such as unmet medical need and supply across member states.

Supply Chains Are Now a Policy Question

For most of the 1990s and 2000s, sourcing an API was a purchasing decision. It is now also a question of trade policy and national security. The clearest sign is where new API registrations come from.

Where new API drug master files filed with FDA came from, 2023

Share of active API DMFs first filed in 2023, by location of the manufacturing site

Horizontal bar chart. India 50 percent, China 32 percent, European Union 10 percent, United States 4 percent, other countries 4 percent. IndiaChinaEuropean UnionUnited StatesOther India: 50% China: 32% European Union: 10% United States: 4% Other countries: 4% 50%32%10%4%4% 0%16%32%48%

Source: US Pharmacopeia analysis reported by RAPS. DMF filings show where new capacity is being offered to the US market; they are not a measure of volume supplied. Across all active API DMFs the split is less extreme (India about 48%, EU 17%, China 16%, US 9%).

Show data
LocationShare of 2023 API DMFs
India50%
China32%
European Union10%
United States4%
Other4%

For comparison, FDA told Congress in 2019 that 28% of the API facilities supplying the US market were in the United States, 26% in the EU, 18% in India and 13% in China. The installed base is more balanced than the new filings suggest, but the direction is clear: new API capacity is being built mainly in India and China.

Governments have responded with a mix of incentives and restrictions:

  • United States – tariffs. A presidential proclamation of 2 April 2026 under Section 232 set a 100% duty on imported patented medicines, reduced to 20% for companies with approved US manufacturing plans and capped at 15% for the EU, Japan, South Korea and Switzerland, and 10% for the UK. Generics, biosimilars and their ingredients are excluded “at this time”, and the Commerce Department is to keep imports under review. The duties applied from 29 September 2026 for most companies. See the Federal Register notice.
  • United States – biotechnology suppliers. The FY2026 National Defense Authorization Act, signed in December 2025, restricts federal agencies and recipients of federal funds from using biotechnology equipment and services from designated “companies of concern”. The first list is due by December 2026, and the restrictions phase in afterwards.
  • European Union – security of supply. EU institutions reached a provisional agreement on the Critical Medicines Act in 2026. It aims to support manufacturing of critical medicines in Europe and to make procurement reward supply security, not only the lowest price.
  • India – self-reliance in starting materials. Production-linked incentive schemes introduced from 2020 support domestic manufacture of key starting materials and APIs previously imported, mainly from China.

Shortages are the background to all of this. ASHP counted a record 323 active US drug shortages in the first quarter of 2024; the count has since eased but remained around 225 in the third quarter of 2026, with sterile injectables and older oncology drugs among the most affected. Many of these are low-price generics where one plant’s failure leaves too few suppliers to cover demand.

What Mattered Then, What Matters Now

Some advantages have lost their force, some have gained it, and some have simply changed form.

Factor1980s2026
Source of advantageA few patented products with long, lightly contested exclusivity.Portfolio choice: entering molecules and dosage forms where few can follow, or owning a defensible innovation.
Route to marketA large sales force visiting doctors.Payers, tenders, purchasing groups and formularies; for generics, reliability of supply wins contracts.
GeographyStrong home market protected by national registration rules.Multi-region dossiers and licensing partners; home-market strength alone is rarely enough.
ManufacturingVertically integrated, owned plants.Mix of owned and contract capacity, with second sources qualified before they are needed.
RegulationApproval was the main hurdle; inspections focused on the plant.Lifelong compliance: data integrity, impurities, serialisation and foreign inspections can remove a product at any time.
TradeTariffs and registration costs protected domestic producers.Tariffs, procurement rules and security laws target specific products, countries and suppliers.
ScaleSize bought research capacity and sales coverage.Size helps only with focus; several of the largest generic deals of the last decade led to heavy write-downs.

What has not changed

Three things would be familiar to a 1980s executive. Quality remains the licence to operate—the difference is that it is now checked continuously and published. Product selection still decides most of the outcome: the right molecule at the right time covers many other weaknesses, and the wrong one cannot be rescued by efficiency. And financial discipline still separates companies that can wait out a bad cycle from those that must sell at the bottom of it.

How Companies Fail: Recurring Patterns

Public cases from the last fifteen years show a small number of repeating patterns. They are useful less as stories than as warning signs to look for in a partner.

Quality and data-integrity failure

Ranbaxy, once India’s largest drugmaker, had sites placed under FDA import alert from 2008 and pleaded guilty in 2013 to charges relating to manufacturing and data practices, paying US$500 million. Akorn, a US maker of injectables and ophthalmics, lost an agreed takeover in 2018 after data-integrity problems were found, filed for bankruptcy in 2020 and closed in 2023. In both cases the commercial collapse followed the quality problem, not the other way round.

Debt taken on at the top of the cycle

Large acquisitions financed with debt assume that prices will hold. When US generic prices fell sharply in 2016–2017, companies that had just paid high prices for generic portfolios faced write-downs, restructuring and, in some cases, years of debt reduction. Several smaller US generic and specialty companies, Lannett among them in 2023, entered Chapter 11 when price erosion met fixed debt obligations.

Concentration in one product, one market or one site

A company dependent on a single product loses it to a new competitor, a recall or a patent ruling. A company dependent on a single plant loses everything to one adverse inspection. A company dependent on a single API source inherits that supplier’s problems. Litigation exposure tied to one product class, as in the opioid cases that pushed several manufacturers into bankruptcy, is a further form of concentration.

Warning signs in a potential partner

Look more closely when a company relies on one product or one site for most of its revenue; has open warning letters, import alerts or repeated inspection observations about data handling; cannot name a qualified second source for critical materials; is entering a molecule that already has many approved suppliers; has recently taken on heavy debt for an acquisition; or depends on a single buyer or tender for most of its volume. None of these is disqualifying alone. Together they describe a company with little room to absorb the next shock.

How Durable Companies Behave

The companies that have come through the last decade in good shape are not all large, and they do not follow one model. They do, however, share observable habits.

  • They choose before they build. Molecule and market selection is a disciplined, data-led process, revisited before every major investment. They exit products that no longer earn their place.
  • They treat quality as a sales argument. A clean inspection history wins tenders and partners. They invest in laboratory systems and staff before an inspector asks.
  • They know their supply chain to the starting material. Critical inputs have qualified alternatives, and supply contracts state who carries the cost of a change.
  • They build dossiers to travel. One technical package is designed from the start to support registrations in several regions, often through licensing partners in markets they will not enter directly.
  • They partner instead of owning everything. Contract manufacturers, licensors and distributors extend reach without fixed cost. The skill is in selecting and managing those partners, a process covered in GXgate’s guide to qualifying an API supplier.
  • They keep financial room. Moderate debt and a spread of revenue let them survive a price collapse or a temporary loss of a product without a forced sale.

Frequently Asked Questions

Why do generic pharmaceutical companies fail?

Most often through a combination of price erosion and concentration: too many products in crowded molecules, too much revenue from one site or market, and too little financial room when prices fall or an inspection goes badly. Quality and data-integrity failures are the most common single trigger.

What made pharmaceutical companies successful in the 1980s?

Patented products with long exclusivity, large sales forces, vertically integrated manufacturing and home markets protected by national registration rules. Generic competition was limited until the 1984 Hatch-Waxman Act opened the US abbreviated approval pathway.

How have trade rules affected the pharmaceutical industry?

Trade liberalisation from the 1990s moved much API and intermediate production to India and China, lowering costs and concentrating supply. Since 2020 the direction has partly reversed: the US introduced Section 232 tariffs on patented medicines in 2026, enacted restrictions on certain biotechnology suppliers, and the EU and India have adopted measures to support domestic production of critical medicines and starting materials.

Are generic medicines subject to the 2026 US pharmaceutical tariffs?

Under the April 2026 proclamation, generics, biosimilars and their associated ingredients are not subject to the Section 232 pharmaceutical tariffs “at this time”. The exclusion is subject to continued review, so companies exporting generics to the US should monitor Federal Register and CBP notices.

Is it still possible for a small pharmaceutical company to succeed?

Yes, but rarely by competing on volume in crowded molecules. Small companies tend to succeed through niche products, difficult dosage forms, specific regional expertise, or by licensing and partnering so that others carry part of the manufacturing or commercial cost.

Choose Partners for the Next Shock, Not the Last One

The industry of 2026 rewards companies that can show their quality record, name their sources and register in more than one region. The same qualities make a good partner. When evaluating a manufacturer, licensor or distributor, ask about the five factors above as directly as you would ask about price.

Find manufacturers, licensors and distribution partners

Search pharmaceutical companies and current offers by product, dosage form, country and capability.

GXgate Pharmaceutical Marketplace
GXgate Pharmaceutical Directory

Public-source review: 17 November 2026. Figures are taken from the sources cited under each chart and in the text; they use different methods and periods and should be read as indicators of direction. Company examples are drawn from public records and are given to illustrate industry patterns, not to assess any company’s current position. Trade and regulatory measures described here change frequently; confirm the current position with the relevant authority and qualified advisers before acting on it.

Log in with your credentials

Forgot your details?